In combination with rhein and atezolizumab, spleen and tumor CD8+ T cell ratios were significantly increased, and the levels of TNF-α, interleukin-6, and various apoptosis factors in the serum under combined therapy were significantly higher than those in other treatment groups, and the growth of breast tumors was effectively inhibited. Here, CD8A is linked to breast neoplasm.